Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice.

Abstract:

BACKGROUND:Allergy immunotherapy (AIT) is the only available treatment that alters the natural course of allergies and has possible disease-modifying effects. AIT is administered primarily via subcutaneous injection delivered in a physician's office. Few studies have been conducted in the United States or Canada to evaluate the costs of subcutaneous immunotherapy (SCIT). OBJECTIVES:To (a) describe SCIT administration processes, resources, and costs and (b) characterize the patient population receiving SCIT. METHODS:A multisite, prospective, observational time and motion study was conducted. Injection and wait times were collected by a third-party observer on 1 visit for each patient. Extract preparation processes were also observed. Site staff reported on treatment protocols, administrative time, supplies, and patient medical history. Patients responded to questionnaires on demographics, reasons for treatment, medication use, productivity, and travel time. Costs were estimated by applying unit costs to the time observations and the patient- and staff-reported data. RESULTS:A total of 670 SCIT patients were enrolled at 6 sites in the United States and 6 sites in Canada. Average age in the United States was 41 years (SD = 18) and 44 years (15) in Canada, with 10% of the patients aged ≥ 65 years. Annual incomes were over $100,000 for 40% of U.S. patients and 30% of Canadian patients. U.S. patients had over 4 times as many different allergens in their SCIT treatments as Canadian patients, with a mean of 18 versus 4. The most common reasons reported for starting SCIT was a "desire to cure allergies once and for all" (73%) and that "symptoms are not improved by allergy medications" (60%). Percentages of patients taking allergy medications in the 4 weeks prior to observation were 86% in the United States and 66% in Canada: antihistamines 75% United States, 54% Canada; inhaled corticosteroids 32% United States, 22% Canada. The predominant comorbidity was asthma, 43% United States, 24% Canada. Site protocols for build-up treatment phases were 1 to 2 injections per week for an average of 25 weeks (range 12-52). Maintenance phases were 1 injection every 3 to 4 weeks for an average of 4 years (range 2.5-5). Eight of the sites had total mean staff times per injection visit of 7 to 22 minutes; 1 site averaged fewer minutes, and 3 sites averaged more. Total direct medical costs were an average of $30 for Canadian patients per visit and $32 per visit for U.S. patients, half accounted for by the cost of the extract. Pre- and postinjection administrative tasks were the second largest driver of direct costs. Total injection visit-related time for patients, including round-trip travel time, averaged about 80 minutes per visit in the United States and in Canada. CONCLUSIONS:Analyses revealed substantial variation in SCIT regimens among sites, but the sites had commonalities in the injection process components. SCIT requires patient commitment to a long-term treatment regimen involving numerous clinic visits and resources for administration.

authors

Blume SW,Yeomans K,Allen-Ramey F,Smith N,Kim H,Lockey RF,Nichol MB

doi

10.18553/jmcp.2015.21.11.982

subject

Has Abstract

pub_date

2015-11-01 00:00:00

pages

982-90

issue

11

eissn

2376-0540

issn

2376-1032

pii

2015(21)11: 0982-0990

journal_volume

21

pub_type

杂志文章,多中心研究
  • Evaluating Patient Preferences for Different Incentive Programs to Optimize Pharmacist-Provided Patient Care Program Enrollment.

    abstract:BACKGROUND:Employers have increased efforts to engage employees in health and wellness programs. Providing employees with incentives to participate in these programs has been shown to improve overall enrollment and engagement. One program that has had challenges with enrollment and engagement is medication therapy mana...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.11.1140

    authors: Tomaszewski D,Cernohous T,Vaidyanathan R

    更新日期:2017-11-01 00:00:00

  • Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data.

    abstract:BACKGROUND:Psoriatic arthritis (PsA) is associated with multiple comorbid conditions, including cardiovascular (CV) comorbidities that impose a considerable burden on patients. Effective management of PsA requires an understanding of comorbidity profiles. OBJECTIVE:To compare the frequency and incidence rates of comor...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.17421

    authors: Kaine J,Song X,Kim G,Hur P,Palmer JB

    更新日期:2019-01-01 00:00:00

  • Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.

    abstract:BACKGROUND:Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB populati...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.9.1072

    authors: Perk S,Wielage RC,Campbell NL,Klein TM,Perkins A,Posta LM,Yuran T,Klein RW,Ng DB

    更新日期:2016-09-01 00:00:00

  • Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.

    abstract:BACKGROUND:Despite multiple treatment options, the prognosis of pulmonary arterial hypertension (PAH) remains poor. PAH patients experience a high economic burden due to comorbidities, hospitalizations, and medication costs. Although combination therapy has been shown to reduce hospitalizations, the relationship betwee...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.17391

    authors: Burger CD,Ozbay AB,Lazarus HM,Riehle E,Montejano LB,Lenhart G,White RJ

    更新日期:2018-08-01 00:00:00

  • Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.

    abstract:BACKGROUND:Tisagenlecleucel was approved for the treatment of pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) based on the pivotal ELIANA trial. OBJECTIVE:To comprehensively evaluate the total costs associated with tisagenlecleucel treatment, including costs ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.20052

    authors: Yang H,Hao Y,Qi CZ,Chai X,Wu EQ

    更新日期:2020-08-01 00:00:00

  • Assessing Quality of Care in Pharmacy: Remembering Donabedian.

    abstract::While some incremental and fragmented progress has been made in recent years, assessing the quality of care provided by pharmacists and pharmacy organizations remains an elusive goal. Revisiting the simple, elegant model of quality assessment originally proposed by physician and scholar Avedis Donabedian can assist ph...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.4.354

    authors: Rupp MT

    更新日期:2018-04-01 00:00:00

  • Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.

    abstract:BACKGROUND:Despite evidence showing the benefits of treatment intensification following an elevated hemoglobin A1c (A1c), clinical inertia, or failure to establish and/or escalate treatment to achieve treatment goals, is a concern among patients diagnosed with type 2 diabetes (T2DM). Clinical inertia may contribute to ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.3.304

    authors: Ruiz-Negrón N,Wander C,McAdam-Marx C,Pesa J,Bailey RA,Bellows BK

    更新日期:2019-03-01 00:00:00

  • Integration Strategies of Pharmacists in Primary Care-Based Accountable Care Organizations: A Report from the Accountable Care Organization Research Network, Services, and Education.

    abstract:BACKGROUND:The accountable care organization (ACO) is an innovative health care delivery model centered on value-based care. ACOs consisting of primary care providers are increasingly becoming commonplace in practice; however, medication management remains suboptimal. PROGRAM DESCRIPTION:As experts in medication manag...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.5.541

    authors: Joseph T,Hale GM,Eltaki SM,Prados Y,Jones R,Seamon MJ,Moreau C,Gernant SA

    更新日期:2017-05-01 00:00:00

  • Real-world evidence enhances decision making.

    abstract::DISCLOSURES: No funding supported the writing of this commentary. The author has nothing to disclose. ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.12.1612a

    authors: Malone DC

    更新日期:2020-12-01 00:00:00

  • The Economic Burden of Opioid Abuse: Updated Findings.

    abstract:BACKGROUND:Opioid pain relievers can be highly effective in providing relief for patients suffering from pain. At the same time, prescription opioid abuse, dependence, overdose, and poisoning (hereinafter "abuse") have become a national public health concern. Opioid abuse is also costly: previous estimates of the annua...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.16265

    authors: Kirson NY,Scarpati LM,Enloe CJ,Dincer AP,Birnbaum HG,Mayne TJ

    更新日期:2017-04-01 00:00:00

  • Twenty Years of Experience and Counting: Strategies for Growing Medication Therapy Management Services.

    abstract:DISCLOSURES:No funding supported the writing of this commentary. Brummel has consulted, presented, or was engaged in an advisory board for UCB, Boerhinger Ingelheim, Pfizer, and Lilly. Sorenson has nothing to disclose. ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.9.1067a

    authors: Brummel AR,Sorensen TD

    更新日期:2020-09-01 00:00:00

  • Evaluation of Bedside Delivery of Medications Before Discharge: Effect on 30-Day Readmission.

    abstract:BACKGROUND:This study is an evaluation of a discharge intervention that occurred in multiple hospitals across Maryland. In this program, patients received medications at their bedside before discharge with the goal of reducing the risk of primary nonadherence to prescribed medications. OBJECTIVE:To test if the interve...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,多中心研究

    doi:10.18553/jmcp.2020.26.3.296

    authors: Segal JB,Apfel A,Brotman DJ,Shermock KM,Clark JM

    更新日期:2020-03-01 00:00:00

  • Optimization of Medication Use at Accountable Care Organizations.

    abstract:BACKGROUND:Optimized medication use involves the effective use of medications for better outcomes, improved patient experience, and lower costs. Few studies systematically gather data on the actions accountable care organizations (ACOs) have taken to optimize medication use. OBJECTIVES:To (a) assess how ACOs optimize ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.10.1054

    authors: Wilks C,Krisle E,Westrich K,Lunner K,Muhlestein D,Dubois R

    更新日期:2017-10-01 00:00:00

  • Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.

    abstract::BACKGROUND: Nonadherence and nonpersistence to antidepressants in major depressive disorder (MDD) are common and associated with poor clinical and functional outcomes and increased health care resource utilization (HCRU) and costs. However, contemporary real-world evidence on the economic effect of antidepressant nona...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2021.27.2.223

    authors: Ta JT,Sullivan SD,Tung A,Oliveri D,Gillard P,Devine B

    更新日期:2021-02-01 00:00:00

  • Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.

    abstract:BACKGROUND:Immunoglobulin (Ig) is a costly blood product prescribed as immune replacement or modulation therapy to treat a wide spectrum of medical conditions. While the FDA has approved Ig for a limited number of indications, there are multiple off-label uses that have demonstrated proven clinical benefit or are curre...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.4.357

    authors: Tonkovic B,Rutishauser LK

    更新日期:2014-04-01 00:00:00

  • Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States.

    abstract::BACKGROUND: The economic burden of food allergy is large; however, costs specific to individuals with peanut allergy experiencing reactions to peanuts remain to be evaluated. As the prevalence of peanut allergy continues to increase in children, a better understanding of the cost of care is warranted. OBJECTIVE: To as...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2021.20389

    authors: Blaiss MS,Meadows JA,Yu S,Robison DR,Hass SL,Norrett KE,Guerin A,Latremouille-Viau D,Tilles SA

    更新日期:2021-01-20 00:00:00

  • The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.

    abstract:BACKGROUND:The management of sickle cell disease (SCD), an inherited, chronic, and multifaceted condition, is associated with considerable health care resource utilization (HRU) and costs, especially for Medicaid. Anemia affects most patients with SCD and correlates with end-organ damage (EOD), such as stroke, chronic ...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.20009

    authors: Campbell A,Cong Z,Agodoa I,Song X,Martinez DJ,Black D,Lew CR,Varker H,Chan C,Lanzkron S

    更新日期:2020-09-01 00:00:00

  • A Retrospective, Longitudinal, Claims-Based Comparison of Concomitant Diagnoses Between Individuals with and Without Down Syndrome.

    abstract:BACKGROUND:Individuals with Down syndrome (DS) experience various comorbidities in excess of the prevalence seen among the non-DS population. However, the extent of the excess burden of comorbidities specifically within commercially and publicly insured DS populations aged < 21 years is not currently known. OBJECTIVES...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.23.7.761

    authors: Kong AM,Hurley D,Evans KA,Brixner D,Csoboth C,Visootsak J

    更新日期:2017-07-01 00:00:00

  • Evaluation of Comprehensive Medication Review Completion Rates Using 3 Patient Outreach Models.

    abstract:BACKGROUND:Medication therapy management (MTM) programs were first introduced as a result of the 2003 Medicare Prescription Drug Improvement and Modernization Act. Since then, the Centers for Medicare & Medicaid Services (CMS) have established minimum requirements for health plans to follow in establishing patient elig...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.7.796

    authors: Miller DE,Roane TE,Salo JA,Hardin HC

    更新日期:2016-07-01 00:00:00

  • Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.

    abstract:BACKGROUND:Adherence to adjuvant endocrine therapy (AET) for estrogen receptor-positive breast cancer remains suboptimal, which suggests that women are not getting the full benefit of the treatment to reduce breast cancer recurrence and mortality. The majority of studies on adherence to AET focus on identifying factors...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2016.22.8.969

    authors: Farias AJ,Hansen RN,Zeliadt SB,Ornelas IJ,Li CI,Thompson B

    更新日期:2016-08-01 00:00:00

  • Current Procedural Terminology Codes for Medication Therapy Management in Administrative Data.

    abstract:BACKGROUND:Three pharmacist-specific Current Procedural Terminology (CPT) codes exist to facilitate medication therapy management (MTM) reimbursement (codes 99605, 99606, and 99607). However, no studies have used CPT codes in administrative claims databases to identify subjects who have received MTM services. OBJECTIV...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2020.26.10.1297

    authors: Axon DR,Chinthammit C,Tate J,Taylor AM,Leal S,Pickering M,Black H,Warholak T,Campbell PJ

    更新日期:2020-10-01 00:00:00

  • The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?

    abstract:BACKGROUND:Accurate estimates of the effects of cost sharing on adherence to medications prescribed for use together, also called concurrent adherence, are important for researchers, payers, and policymakers who want to reduce barriers to adherence for chronic condition patients prescribed multiple medications concurre...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2015.21.8.678

    authors: Sacks NC,Burgess JF,Cabral HJ,McDonnell ME,Pizer SD

    更新日期:2015-08-01 00:00:00

  • Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.

    abstract:BACKGROUND:Clinical trials impose exclusion criteria that may limit the generalizability of results. OBJECTIVES:To (a) determine the percentage of real-world patients who would qualify for psoriasis randomized controlled trials; (b) ascertain differences between moderate-to-severe psoriasis patients who would be eligi...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2017.16367

    authors: Malatestinic W,Nordstrom B,Wu JJ,Goldblum O,Solotkin K,Lin CY,Kistler K,Fraeman K,Johnston J,Hawley LL,Sicignano N,Araujo A

    更新日期:2017-03-01 00:00:00

  • The Effect of Florida Medicaid's State-Mandated Formulary Provision on Prescription Drug Use and Health Plan Costs in a Medicaid Managed Care Plan.

    abstract:BACKGROUND:Formulary or preferred drug list (PDL) management is an effective strategy to ensure clinically efficient prescription drug management by managed care organizations (MCOs). Medicaid MCOs participating in Florida's Medicaid program were required to use a state-mandated PDL between May and August 2014. OBJECT...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.2.124

    authors: Munshi KD,Mager D,Ward KM,Mischel B,Henderson RR

    更新日期:2018-02-01 00:00:00

  • Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

    abstract:BACKGROUND:New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and economic outcomes across all approved regimens. OBJECTIVE:To evaluate the cost-effectiveness of trea...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.1.29

    authors: Carlson JJ,Guzauskas GF,Chapman RH,Synnott PG,Liu S,Russo ET,Pearson SD,Brouwer ED,Ollendorf DA

    更新日期:2018-01-01 00:00:00

  • The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.

    abstract:BACKGROUND:Several authors have hypothesized that adverse drug events (ADEs) upon switching from reference biologics to biosimilar products are related to the nocebo effect. However, a thorough and current review of the existing literature has not been conducted. OBJECTIVE:To evaluate if patient and/or physician knowl...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2018.24.10.952

    authors: Odinet JS,Day CE,Cruz JL,Heindel GA

    更新日期:2018-10-01 00:00:00

  • Letter--The Authors Respond.

    abstract:DISCLOSURES:No additional funding was received for the writing of this letter. The published study referred to in this letter was funded by Janssen Scientific Affairs, which employs Maiese and funded Cornerstone Research Group, a health economic consulting group, to conduct the study. Grima is a founding partner of Cor...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2019.25.9.1028

    authors: Hollmann S,Moldaver D,Goyert N,Grima D,Maiese EM

    更新日期:2019-09-01 00:00:00

  • The Effectiveness and Value of Treatments for Spinal Muscular Atrophy.

    abstract:DISCLOSURES:Funding for this summary was contributed by the Laura and John Arnold Foundation and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is s...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,评审

    doi:10.18553/jmcp.2019.25.12.1300

    authors: Pearson SD,Thokala P,Stevenson M,Rind D

    更新日期:2019-12-01 00:00:00

  • Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

    abstract:BACKGROUND:Adjuvant trastuzumab treatment is administered to early stage breast cancer patients in physician office (POV) or hospital outpatient (HOP) settings. OBJECTIVE:To identify treatment patterns, utilization, and costs by site of care (POV vs. HOP) of patients with adjuvant treatment of breast cancer with trast...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章

    doi:10.18553/jmcp.2014.20.5.485

    authors: Parthan A,Santos E,Becker L,Small A,Lalla D,Brammer M,Teitelbaum A

    更新日期:2014-05-01 00:00:00

  • Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.

    abstract:BACKGROUND:Tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for patients suffering from chronic myeloid leukemia (CML). Testing for various mutations in the BCR-ABL gene may help predict lack of response to specific TKIs where resistance has developed. OBJECTIVE:To estimate the emergence of BCR-ABL kinase...

    journal_title:Journal of managed care & specialty pharmacy

    pub_type: 杂志文章,meta分析

    doi:10.18553/jmcp.2015.21.2.114

    authors: Ursan ID,Jiang R,Pickard EM,Lee TA,Ng D,Pickard AS

    更新日期:2015-02-01 00:00:00